Uterine Cancer Drugs Market - Size, Share, Outlook,
and Opportunity Analysis, 2018-2026
Uterine cancer is one of the most common gynecologic malignancy among female cancer
patients. This uterine cancer is of two types: endometrial cancer and uterine sarcoma.
Endometrial cancer is caused due to uncontrolled growth of inner linings of uterus. Endometrial
cancer is often curable, however, uterine sarcoma is rare cancer, which develops in the muscle
and supporting tissues of the uterus (womb). According to National Cancer Institute, Megestrol
Acetate is only drug approved by U.S. Food and Drug Administration (FDA) for the treatment of
endometrial cancer till March 2016. Diagnosis of both types of uterine cancer is done through
endometrial biopsy, colposcopy or Pap smear screening test.
Request Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/1745
Uterine Cancer Drugs Market Drivers
Increasing funding for cancer research, rising insurance coverage, and increasing number of new
targeted cancer drugs are supporting the revenue growth of uterine cancer drugs market size.
For instance, National Cancer Institute, in 2015, invested around US$ 4,480 million on cancer
research, which include uterine cancer, cervical cancer, lung cancer, colorectal cancer, liver
cancer, breast cancer, leukemia, and ovarian cancer. Furthermore, according to the American
Cancer Society, U.S. has spent around US$ 87.8 billion in 2014, on cancer research, in which
the major cost accounting for around 44%, was paid by private insurance companies.
Chemotherapy is the most recommended therapy suggested for treatment of uterine sarcomas.
However, chemotherapy may not work in certain types of uterine sarcoma. Chemotherapy for
uterine sarcoma is often conducted in the earlier stages of cancer. Various chemotherapy drugs
used in the treatment of uterine sarcoma include Paclitaxel (Taxol), Docetaxel (Taxotere),
Dacarbazine (DTIC), Liposomal doxorubicin (Doxil), Epirubicin (Ellence), and among others.
Report includes chapters which deeply display the following deliverable about industry :
• Uterine Cancer Drugs Market Research Objective and Assumption
• Uterine Cancer Drugs Market Purview - Report Description, Executive Summary, and Coherent